DDS-06E

DDS-06E is an experimental oral pH‑sensitive micellar formulation of the topoisomerase I inhibitor SN38, designed to enable effective oral delivery of this highly insoluble and efflux‑transported active metabolite of irinotecan. Preclinical studies using Caco‑2 cell models have shown that DDS-06E incorporates efflux pump inhibitors to enhance intestinal absorption of SN38, while xenograft models of human colon and pancreatic cancer in Swiss nude mice have demonstrated antitumor efficacy and tolerability with various oral dosing regimens.[7][8][4][1] The formulation is based on Labopharm’s Polymeric Nano‑Delivery Systems (PNDS) technology platform for oral delivery of hydrophobic drugs and has been proposed as a candidate for future clinical evaluation in solid tumors, particularly colorectal and pancreatic cancers.[10][1][12]